Efficacy and safety of widely used treatments for macular oedema secondary to retinal vein occlusion: A systematic review

BMC Ophthalmology

Volumn 14, Issue 1, 2014, Pages

  Glanville, Julie ^a   Patterson, Jacoby ^a   McCool, Rachael ^a   Ferreira, Alberto ^b   Gairy, Kerry ^b   Pearce, Ian ^c  

^a UNIVERSITY OF YORK   (United Kingdom)

^b Royal Liverpool University Hospitals NHS Trust ^*

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Branch retinal vein occlusion; Central retinal vein occlusion; Dexamethasone intravitreal; Laser; Ranibizumab; Retinal vein occlusion

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT; DEXAMETHASONE; MONOCLONAL ANTIBODY; RANIBIZUMAB;

HUMAN; LOW LEVEL LASER THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; REVIEW; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; DEXAMETHASONE; HUMANS; LASER THERAPY; MACULAR EDEMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETINAL VEIN OCCLUSION; VISUAL ACUITY;

EID: 84892571554     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/1471-2415-14-7     Document Type: Review

References (65)

1. Branch retinal vein occlusion: classification and treatment. Parodi MB, Bandello F, Ophthalmologica 2009 223 5 298 305 10.1159/000213640 19372724
2. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Hayreh SS, Zimmerman MB, Podhajsky P, Am J Ophthalmol 1994 117 4 429 441 8154523 (Pubitemid 24115701)
3. Clinical practice. Retinal-vein occlusion. Wong TY, Scott IU, N Engl J Med 2010 363 22 2135 2144 10.1056/NEJMcp1003934 21105795
4. Retinal vein occlusion (RVO): interim guidelines for management of retinal vein occlusion (RVO). Royal College of Ophthalmologists, London: RCOpth 2010 Available from: http://www.rcophth.ac.uk/core/core-picker/download.asp?id= 337
5. Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. Yau JW, Lee P, Wong TY, Best J, Jenkins A, Intern Med J 2008 38 12 904 910 10.1111/j.1445-5994.2008.01720.x 19120547
6. Argon laser photocoagulation for macular edema in branch vein occlusion. The branch vein occlusion study group. BVOS, Am J Ophthalmol 1984 98 3 271 282 6383055
7. Natural history of central retinal vein occlusion: an evidence-based systematic review. McIntosh RL, Rogers SL, Lim L, Cheung N, Wang JJ, Mitchell P, Kowalski JW, Nguyen HP, Wong TY, Ophthalmology 2010 117 6 1113 1123 e1115 10.1016/j.ophtha.2010.01.060 20430446
8. Vision-related quality of life in persons with unilateral branch retinal vein occlusion using the 25-item national eye institute visual function questionnaire. Awdeh RM, Elsing SH, Deramo VA, Stinnett S, Lee PP, Fekrat S, Br J Ophthalmol 2010 94 3 319 323 10.1136/bjo.2007.135913 19737736
9. Vision-related quality of life in people with central retinal vein occlusion using the 25-item national eye institute visual function questionnaire. Deramo VA, Cox TA, Syed AB, Lee PP, Fekrat S, Arch Ophthalmol 2003 121 9 1297 1302 10.1001/archopht.121.9.1297 12963613 (Pubitemid 37128408)
10. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The central vein occlusion study group. CVOS, Ophthalmology 1995 102 10 1425 1433 9097788
11. Impact of severity and bilaterality of visual impairment on health-related quality of life. Varma R, Wu J, Chong K, Azen SP, Hays RD, Ophthalmology 2006 113 10 1846 1853 10.1016/j.ophtha.2006.04.028 16889831 (Pubitemid 44442430)
12. Ozurdex summary of product characteristics last updated December 2011. Available at: http://www.medicines.org.uk/emc/medicine/23422/SPC/ozurdex/. Accessed July 2012
13. Lucentis prescribing information (US) last updated June 2010. Available at: http://www.gene.com/gene/products/information/pdf/lucentis-prescribing.pdf. Accessed July 2012
14. Ozurdex prescribing information (US) last updated February 2012. Available at: http://www.allergan.com/assets/pdf/ozurdex-pi.pdf. Accessed July 2012
15. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Pieramici DJ, Rabena M, Castellarin AA, Nasir M, See R, Norton T, Sanchez A, Risard S, Avery RL, Ophthalmology 2008 115 10 47 54 10.1016/j.ophtha.2008.06.021 18708258
16. Effect of triamcinolone acetonide on vascular endothelial growth factor and occludin levels in branch retinal vein occlusion. McAllister IL, Vijayasekaran S, Chen SD, Yu DY, Am J Ophthalmol 2009 147 5 838 846 e831-832 10.1016/j.ajo.2008.12.006 19211093
17. Nonsteroidal and steroidal anti-inflammatory agents. Leopold IH, Surgical Pharmacology of the Eye New York: Raven Press, Sears ML, Tarkkanen A, 1985 83 133
18. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, et al. Ophthalmology 2010 117 6 1134 1146 e1133 10.1016/j.ophtha.2010.03.032 20417567
19. Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Koss MJ, Pfister M, Rothweiler F, Michaelis M, Cinatl J, Schubert R, Koch FH, Acta Ophthalmol 2012 90 2 98 e103 10.1111/j.1755-3768.2011.02292.x 22066978
20. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, Whitcup SM, Arch Ophthalmol 2007 125 3 309 317 10.1001/archopht.125.3.309 17353400 (Pubitemid 46425557)
21. Correlation of inflammatory and proangiogenic cytokines from undiluted vitreous samples with spectral domain OCT scans, in untreated branch retinal vein occlusion. Pfister M, Rothweiler F, Michaelis M, Cinatl J Jr, Schubert R, Koch FH, Koss MJ, Clin Ophthalmol 2013 7 1061 1067 23766628
22. Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Wang K, Wang Y, Gao L, Li X, Li M, Guo J, Biol Pharm Bull 2008 31 8 1541 1546 10.1248/bpb.31.1541 18670086
23. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Chan CK, Gonzalez VH, Singerman LJ, Tolentino M, Arch Ophthalmol 2009 127 9 1115 1128 19752420
24. Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Zhang X, Bao S, Lai D, Rapkins RW, Gillies MC, Diabetes 2008 57 4 1026 1033 10.2337/db07-0982 18174522
25. Eylea prescribing information (US) last updated September 2012. Available at: http://www.regeneron.com/Eylea/eylea-fpi.pdf. Accessed July 2012
26. Center for Reviews and Dissemination, Systemtic Reviews: CRD's guidance for undertaking reviews in health care York: CRD, University of York 2009
27. Gray S, Rubio R, A phase III, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection compared with sham in subjects with macular edema secondary to branch retinal vein occlusion [Clinical Study Report] Genentech: South San Francisco, CA 2009
28. Gray S, Rubio R, A phase III, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection compared with sham in subjects with macular edema secondary to branch retinal vein occlusion [Clinical Study Report Addendum] Genentech: South San Francisco, CA 2009
29. Gray S, Rubio R, A phase III, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection compared with sham in subjects with macular edema secondary to central retinal vein occlusion [Clinical Study Report] Genentech: South San Francisco, CA 2010
30. Gray S, Rubio R, A phase III, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection compared with sham in subjects with macular edema secondary to central retinal vein occlusion [Clinical Study Report Addendum] Genentech: South San Francisco, CA 2010
31. Subgroup analyses of visual acuity outcomes in the bravo study of intravitreal ranibizumab in patients with macular edema following branch retinal vein occlusion. Singer M, Gray S, Yee Murahashi W, Saroj N, Rundle A, Rubio R, ARVO Meeting Abstracts 2010 51 3561 Available from: http://abstracts.iovs.org// cgi/content/abstract/51/5/3561
32. Shyangdan D, Cummins E, Lois N, Royle P, Waugh N, Dexamethasone implants (Ozurdex) for macular oedema after retinal vein occlusion. Single technology appraisal (STA) AbHTAG 2010 Available from: http://www.nice.org.uk/nicemedia/ live/13037/52883/52883.pdf
33. Allergan, Dexamethasone intravitreal implant (Ozurdex®) for the treatment of macular oedema caused by retinal vein occlusion. Single technology appraisal (STA) Allergan 2010 Available from: http://www.nice.org.uk/nicemedia/ live/13037/52863/52863.pdf
34. Allergan, A study of the safety and efficacy of a new treatment for macular edema resulting from retinal vein occlusion. NCT00168298 2009 Available from: http://ClinicalTrials.gov/show/NCT00168298
35. Allergan, A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion. NCT00168324 2009 Available from: http://ClinicalTrials.gov/show/NCT00168324
36. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR, Arch Ophthalmol 2007 125 11 1460 1469 10.1001/archopht.125.11.1460 17998507 (Pubitemid 350106676)
37. Development of the 25-item national eye institute visual function questionnaire. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD, Arch Ophthalmol 2001 119 7 1050 1058 10.1001/archopht.119.7.1050 11448327 (Pubitemid 32652197)
38. Vision-specific instruments for the assessment of health-related quality of life and visual functioning: a literature review. Margolis MK, Coyne K, Kennedy-Martin T, Baker T, Schein O, Revicki DA, Pharmacoeconomics 2002 20 12 791 812 10.2165/00019053-200220120-00001 12236802 (Pubitemid 35216491)
39. Report from the NEI/FDA ophthalmic clinical trial design and endpoints symposium. Csaky KG, Richman EA, Ferris FL 3rd, Invest Ophthalmol Vis Sci 2008 49 2 479 489 10.1167/iovs.07-1132 18234989
40. NICE, Single technology appraisal (STA). Specification for manufacturer/sponsor submission of evidence London: NICE 2009
41. PBAC, Report of the Indirect Comparisons Working Group to the Pharmaceutical Benefits Advisory Committee: assessing indirect comparisons PBAC 2008 Available from: http://www.pbs.gov.au/industry/useful-resources/PBAC- feedback-files/ICWG%20Report%20FINAL2.pdf
42. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY, Ophthalmology 2010 117 6 1124 1133 e1121 10.1016/j.ophtha.2010.02.022 20381871
43. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG, Ophthalmology 2010 117 6 1102 1112 e1101 10.1016/j.ophtha.2010.02.021 20398941
44. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study. Kinge B, Stordahl PB, Forsaa V, Fossen K, Haugstad M, Helgesen OH, Seland J, Stene-Johansen I, Am J Ophthalmol 2010 150 3 310 314 10.1016/j.ajo.2010.03.028 20591399
45. Grid laser treatment of macular edema in macular branch retinal vein occlusion. Battaglia Parodi M, Saviano S, Bergamini L, Ravalico G, Doc Ophthalmol 1999 97 3-4 427 431 10896360
46. Panretinal photocoagulation in central retinal vein occlusion: a randomised controlled clinical study. Laatikainen L, Kohner EM, Khoury D, Blach RK, Br J Ophthalmol 1977 61 12 741 753 10.1136/bjo.61.12.741 341965 (Pubitemid 8283146)
47. Xenon arc panretinal photocoagulation for central retinal vein occlusion: a randomised prospective study. May DR, Klein ML, Peyman GA, Raichand M, Br J Ophthalmol 1979 63 11 725 734 10.1136/bjo.63.11.725 508687 (Pubitemid 10236313)
48. Faghihi H, Piri N, Esfahani M, Aalami Z, Lashay A, Piri N, Faghihi S, Intravitreal bevacizumab vs. combination of bevacizumab and triamcinolone vs. sham treatment in Central Retinal Vein Occlusion American Academy of Ophthalmology Meeting Archives 2008 271 Available from: http://aao. scientificposters.com/epsView.cfm? 8o86zyfE5SMw0%2FURIHEaEPee1tSQzRJzYw6PAGSTN9mNNuonO4x%2FYg%3D%3D
49. Intravitreal bevacizumab vs. sham treatment in acute branch retinal vein occlusion with macular edema: results at 3 months (Report 1). Moradian S, Faghihi H, Sadeghi B, Piri N, Ahmadieh H, Soheilian M, Dehghan MH, Azarmina M, Esfahani MR, Graefes Arch Clin Exp Ophthalmol 2011 249 2 193 200 10.1007/s00417-010-1440-8 21337043
50. Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Russo V, Barone A, Conte E, Prascina F, Stella A, Noci ND, Retina 2009 29 4 511 515 10.1097/IAE. 0b013e318195ca65 19174717
51. The National Institute for Health and Clinical Excellence, Guide to the methods of technology appraisal last updated June 2008 2012 Available at: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf
52. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG, Murahashi WY, Ophthalmology 2011 118 8 1594 1602 10.1016/j.ophtha.2011.02.022 21684606
53. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG, Ophthalmology 2011 118 10 2041 2049 10.1016/j.ophtha.2011.02.038 21715011
54. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, et al. Ophthalmology 2011 118 12 2453 2460 10.1016/j.ophtha.2011.05.014 21764136
55. Ranibizumab for macular edema due to retinal vein occlusions long-term follow-up in the HORIZON trial. Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, Lai P, Ophthalmology 2012 119 4 802 809 10.1016/j.ophtha.2011.12.005 22301066
56. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, N Engl J Med 2006 355 14 1432 1444 10.1056/NEJMoa062655 17021319 (Pubitemid 44511558)
57. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL III, Friedman SM, Glassman AR, Miller KM, et al. Ophthalmology 2010 117 6 1064 1077 e1035 10.1016/j.ophtha.2010.02.031 20427088
58. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N, Am J Ophthalmol 2008 145 2 239 248 10.1016/j.ajo.2007.10.004 18222192
59. Perspectives on diabetic retinopathy. Aiello LM, Am J Ophthalmol 2003 136 1 122 135 10.1016/S0002-9394(03)00219-8 12834680 (Pubitemid 36794505)
60. Photocoagulation of diabetic macular oedema complications and visual outcome. Lovestam-Adrian M, Agardh E, Acta Ophthalmol Scand 2000 78 6 667 671 10.1034/j.1600-0420.2000.078006667.x 11167229
61. Modified grid laser photocoagulation for diabetic macular edema. The effect on the central visual field. Striph GG, Hart WM Jr, Olk RJ, Ophthalmology 1988 95 12 1673 1679 10.1016/S0161-6420(88)32957-X 3231435 (Pubitemid 19000630)
62. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Boyer D, Heier J, Brown DM, Clark WL, Vitti R, Berliner AJ, Groetzbach G, Zeitz O, Sandbrink R, Zhu X, et al. Ophthalmology 2012 119 5 1024 1032 10.1016/j.ophtha.2012.01.042 22440275
63. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, Zeitz O, Sandbrink R, Zhu X, Haller JA, Am J Ophthalmol 2013 155 3 429 437 e427 10.1016/j.ajo.2012.09. 026 23218699
64. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Holz FG, Roider J, Ogura Y, Korobelnik JF, Simader C, Groetzbach G, Vitti R, Berliner AJ, Hiemeyer F, Beckmann K, et al. Br J Ophthalmol 2013 97 3 278 284 10.1136/bjophthalmol- 2012-301504 23298885
65. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Korobelnik JF, Holz FG, Roider J, Ogura Y, Simader C, Schmidt-Erfurth U, Lorenz K, Honda M, Vitti R, Berliner AJ, et al. Ophthalmology 2013 121 1 202 208 24084497